A small biotech that got hammered by investors when it unveiled disappointing results from a Phase 2 clinical trial of its Alzheimer’s drug last spring will report better news on Sunday. After following patients with advanced Alzheimer’s for an additional two weeks, Neurotrope (NTRP) found that the improved cognitive scores of those on a low dose of the compound, bryostatin, were large enough compared to patients in the control group to come within a whisker of statistical significance. And in subsets of the low-dose patients, the  cognitive improvement cleared that statistical bar.

All of the follow-on analyses, which Neurotrope president and chief scientific officer Dr. Daniel Alkon will present at the Sachs’ Neuroscience Innovation Forum in San Francisco, were pre-specified in the statistical plan for the clinical trial, not post hoc — which is considered statistically suspect.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy